FLT3 and acute myeloid leukemia: However, CR rates and disease-free survival rates were similar between therapies with or without midostaurin in the Randomized Adjuvant Treatment for Initial FLT3-mutated Young adults with AML (RATIFY) trial (NCT00651261).